Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Effects of NSAIDs on the osteogenic differentiation of human adipose tissue-derived stromal cells.

Hadjicharalambous C., Alexaki VI., Alpantaki K., Chatzinikolaidou M.

Laboratory Study on Chronic Inflammation, published in J Pharm Pharmacol (2016) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
J Pharm Pharmacol (2016)
Country
England
Reported sample size
—
Source database
PubMed
PMID
27523985
DOI
10.1111/jphp.12595

Abstract (original English)

Non-steroidal anti-inflammatory drugs (NSAIDs), used in the treatment of musculoskeletal pathologies, have been associated with impaired bone healing, possibly through inhibition of osteogenic differentiation. The adipose tissue (AT) is regarded as an attractive source of stromal cells for autologous cell transplantation in the bone. The effects of NSAIDs on human AT-derived stromal cells (hADSCs) are unknown. We examined the effect of several NSAIDs including meloxicam, parecoxib, lornoxicam, diclofenac and paracetamol on the proliferation of hADSCs by means of the PrestoBlue ® viability assay, and the osteogenic differentiation capacity of hADSCs by means of the alkaline phosphatase (ALP) activity, calcium deposition by alizarin red staining and osteogenic gene expression by semi-quantitative PCR. Most of the drugs enhanced hADSC cell growth, while either positively affecting or not influencing alkaline phosphatase (ALP) activity, calcium deposition and osteogenic gene expression. Moreover, selective COX-2 inhibitor NSAIDs, such as meloxicam or parecoxib, were advantageous over the non-selective COX-1 and COX-2 inhibitor NSAIDs lornoxicam and diclofenac. Altogether through this study, we show that NSAIDs, possibly depending on their selectivity for COX inhibition, leave the osteogenic differentiation capacity of hADSCs unaltered or might even enhance it.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAlkaline PhosphataseAnti-Inflammatory Agents, Non-SteroidalCalcification, PhysiologicCalciumCell DifferentiationCell ProliferationCells, CulturedCyclooxygenase 1Cyclooxygenase 2

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research